Ybrain Completes Patient Enrollment for Dementia Electronic Drug Clinical Trial

[Asia Economy Reporter Chunhee Lee] Electronic medicine platform company Ybrain announced on the 3rd that it has completed patient enrollment for the Phase 3 clinical trial of its developing mild cognitive impairment electronic medicine (transcranial direct current stimulator).

This clinical trial aims to evaluate the efficacy and safety of Ybrain's dementia electronic medicine in improving cognitive function and will be conducted on 118 participants. It will take place at six university hospitals in Korea, including Korea University Anam Hospital, Incheon St. Mary's Hospital, and Soonchunhyang University Cheonan Hospital.

Since 2015, Ybrain has been conducting exploratory clinical trials of electronic medicine for dementia patients. Subsequently, it received approval for the confirmatory clinical trial plan from the Ministry of Food and Drug Safety and completed patient recruitment last month. Ybrain plans to submit the results report within this year after a six-month home treatment period and aims to obtain marketing approval from the Ministry as early as the beginning of next year.

Lee Gi-won, CEO of Ybrain, stated, “Following the approval of electronic medicine for depression, the approval clinical trial for dementia electronic medicine best represents Ybrain's corporate identity,” adding, “Along with the prescription electronic medicine pipeline, we will sequentially conduct clinical trials for general electronic medicine pipelines and achieve a technology-specialized stock listing within this year.”

This content was produced with the assistance of AI translation services.